Cargando…

Robust COVID-19 vaccination response after allogeneic stem cell transplantation using post transplantation cyclophosphamide conditioning

Detalles Bibliográficos
Autores principales:	Morsink, L. M., van Doesum, J., Choi, G., Hazenberg, C. L. E., Biswana, A., Meppelink, F., Bungener, L. B., Lambeck, A. J. A., Huls, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754065/ https://www.ncbi.nlm.nih.gov/pubmed/35022420 http://dx.doi.org/10.1038/s41408-021-00605-1

Ejemplares similares

Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant
por: Zhao, Chenchen, et al.
Publicado: (2022)

Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation
por: Duléry, Rémy, et al.
Publicado: (2021)

Risk factors associated with the development of moderate to severe chronic graft-versus-host disease after non-myeloablative conditioning allogeneic stem cell transplantation in patients with AML or MDS
por: Kok, Laurence M. C., et al.
Publicado: (2019)

Immune reconstitution profile after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide
por: Espinoza-Gutarra, Manuel, et al.
Publicado: (2023)

Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide
por: Greco, Raffaella, et al.
Publicado: (2019)

Haploidentical Hematopoietic Stem Cell Transplantation Followed by ‘Post-Cyclophosphamide’: The Future of Allogeneic Stem Cell Transplant
por: Cytryn, Samuel, et al.
Publicado: (2020)

Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post‐transplant cyclophosphamide
por: Jullien, Maxime, et al.
Publicado: (2021)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
por: Joshi, Maansi, et al.
Publicado: (2021)

Impacts of post-transplantation cyclophosphamide treatment after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
por: Namdaroglu, Sinem, et al.
Publicado: (2019)

The Benefits of the Post-Transplant Cyclophosphamide in Both Haploidentical and Mismatched Unrelated Donor Setting in Allogeneic Stem Cells Transplantation
por: Dybko, Jarosław, et al.
Publicado: (2023)

Is there any difference between busulfan-cyclophosphamide and cyclophosphamide-busulfan in patients underwent allogeneic transplantation?
por: Bahçecioğlu, Ömer Faruk, et al.
Publicado: (2021)

Post-Transplant Cyclophosphamide for the Prevention of Graft-vs.-Host Disease in Allogeneic Hematopoietic Cell Transplantation: A Guide to Management for the Advanced Practitioner
por: Kachur, Ekaterina, et al.
Publicado: (2023)

Infective hyperammonaemic encephalopathy after allogeneic stem cell transplant
por: Shipton, Michael J., et al.
Publicado: (2022)

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

Lipidomics of cyclophosphamide 4‐hydroxylation in patients receiving post‐transplant cyclophosphamide
por: Navarro, Sandi L., et al.
Publicado: (2022)

Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2021)

Azacitidine in Combination with Venetoclax Maintenance Post-allogeneic Hematopoietic Stem Cell Transplantation in T Cell Acute Lymphoblastic Leukemia
por: Hassan, Mona Ali, et al.
Publicado: (2023)

Is Post-Transplant Cyclophosphamide the New Methotrexate?
por: Mussetti, Alberto, et al.
Publicado: (2021)

Significance of men’s health in long-term survivors of allogeneic stem cell transplantation
por: Schneidewind, Laila, et al.
Publicado: (2022)

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide
por: Munchel, Ashley, et al.
Publicado: (2011)

Post-Transplantation Cyclophosphamide: An Old Nemesis to a New Transplant Paradigm?
por: Rotz, Seth J., et al.
Publicado: (2021)

Tumour-reactive B cells and antibody responses after allogeneic haematopoietic cell transplantation
por: de Jong, G., et al.
Publicado: (2020)

PB2190: HLA-HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER REDUCED-INTENSITY CONDITIONING
por: Kim, J., et al.
Publicado: (2022)

COVID-19 in recipients of allogeneic stem cell transplantation: favorable outcome
por: Lupo-Stanghellini, Maria Teresa, et al.
Publicado: (2021)

Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma
por: Yang, Luxin, et al.
Publicado: (2018)

S114: FEASIBILITY OF HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR PATIENTS WITH SEVERE SICKLE CELL DISEASE WITH END-STAGE RENAL DISEASE (ESRD) ON HEMODIALYSIS
por: Gomez Arteaga, A, et al.
Publicado: (2022)

Alveolar levels of immuno-inflammatory mediators in diffuse alveolar hemorrhage after allogeneic transplant
por: Vande Vusse, Lisa K., et al.
Publicado: (2018)

Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia
por: Pophali, Prateek, et al.
Publicado: (2020)

Efficacy of low-dose zoster prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation
por: Mascarenhas, Kristen, et al.
Publicado: (2019)

Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant
por: Sora, Federica, et al.
Publicado: (2022)

Cyclophosphamide-Induced Tolerance in Allogeneic Transplantation: From Basic Studies to Clinical Application
por: Kato, Koji, et al.
Publicado: (2020)

Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey
por: Sellner, Leopold, et al.
Publicado: (2020)

Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma
por: Yang, Fan, et al.
Publicado: (2022)

Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia
por: Lazzari, Lorenzo, et al.
Publicado: (2022)

Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant
por: Pabon, Cindy M., et al.
Publicado: (2021)

Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia
por: Baranwal, Anmol, et al.
Publicado: (2022)

Cerebral toxoplasmosis after allogeneic hematopoietic stem cell transplantation diagnosed by megagenomic analysis
por: Shen, Kai, et al.
Publicado: (2019)

Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection
por: Christopeit, Maximilian, et al.
Publicado: (2021)

Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation
por: Mehdizadeh, Mahshid, et al.
Publicado: (2021)

Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease
por: van Lier, Yannouck F., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2g5ijfbq7n9lroo1tk1ecptivl